Skip to main content
Message Font: Serif | Sans-Serif
No. of Recommendations: 0

Lilly: Like the Flower, Not the Stock
By Stephen D. Simpson, CFA (TMFWildWeasel)
April 20, 2006

It's easy to find yourself paralyzed like a deer in headlights when deciding which stock(s) to buy. There's the fabled "paralysis by analysis," where you spend all of your time looking for just one more detail and you never end up doing anything. There's also what I call paralysis by abundance -- that is, freezing up when you know you want to get into a sector, but there's several potentially promising candidates.

I can see how that would be true these days in the big-cap drug sector. Particularly because you have a mix of depressed stories like Merck (NYSE: MRK) and Pfizer (NYSE: PFE), recovery stories like Wyeth (NYSE: WYE) and Schering-Plough (NYSE: SGP), and then still more like AstraZeneca (NYSE: AZN) and Lilly (NYSE: LLY). It's Motley Fool Income Investor recommendation Lilly that we'll be considering here.....
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.